Study on How One Night Without Sleep Affects Alzheimers Biomarkers in Healthy Adults Aged 18 to 40 With Different APOE Genes

What this Trial Is About

Researchers are investigating how 24 hours of acute sleep deprivation affects plasma Alzheimers disease biomarkers and multi-omics in healthy adults with different APOE genotypes. This study aims to better understand the possible role of short-term sleep loss in Alzheimers disease risk by comparing groups with APOE 33, APOE 4 carriers, and APOE 2 carriers. The trial involves 60 volunteers and uses a randomized controlled design to explore these effects across genetic differences. Participants will be randomly assigned to one of two groups within their APOE genotype category one group will undergo 24 hours of sleep deprivation without naps, while the other will follow a normal 24-hour work-rest schedule. The study uses stratified randomization to ensure equal representation across the three genotype groups and interventions. The primary focus is on changes in plasma A2 levels measured one day after the intervention. During the study, participants plasma biomarkers related to Alzheimers disease will be measured, including several tau proteins and neurofilament light chain, along with assessments of fatigue, mood, and cognitive performance through specific scales and tasks. Researchers will monitor these outcomes one day after randomization to evaluate the effects of sleep deprivation. Participants will be healthy adults aged 18 to 40, and their sleep habits and cognitive status will be evaluated to ensure eligibility. The study includes monitoring for safety and adherence during the 24-hour intervention period.

Effects of Acute Sleep Deprivation on Individuals With Different APOE Genotypes